BioCardia, Inc. (BCDA) stock

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.83+0.01 (+0.61%)

Close on Nov 13, 2026Market cap $12.58MP/E –Yield –

BioCardia price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

BioCardia's price to book ratio was 5.1× on Nov 11, 2026, against 11.0× a year earlier. Over the last 5 years it ranged from 3.6× to 425.8×, with a median of 50.9×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	5.1×	+0.1
2025	Dec 31, 2025	5.0×	+1.5
2024	Dec 31, 2024	3.6×	−69.7
2023	Oct 31, 2023	73.3×	−63.2
2022	Dec 30, 2022	136.5×	+99.9
2021	Dec 31, 2021	36.6×	−120.2
2020	Dec 31, 2020	156.8×	+84.3
2019	Dec 31, 2019	72.5×	−161.5
2018	Dec 31, 2018	234.0×	+136.5
2017	Dec 29, 2017	97.6×	−92.3
2016	Dec 30, 2016	189.9×	+170.4
2015	Dec 31, 2015	19.5×	−7.9
2014	Dec 31, 2014	27.4×	+7.2
2013	Dec 31, 2013	20.2×	+5.0
2012	Dec 31, 2012	15.2×	−2.5
2011	Dec 30, 2011	17.7×	–